open access

Vol 60, No 5 (2009)
Original papers
Published online: 2009-10-30
Submitted: 2013-02-15
Get Citation

Dyslipidaemia and its management in diabetic patients in an academic centre in Iran

Elham Faghihimani, Peyman Adibi, Masoud Amini
Endokrynologia Polska 2009;60(5):353-356.

open access

Vol 60, No 5 (2009)
Original papers
Published online: 2009-10-30
Submitted: 2013-02-15

Abstract


Introduction: Dyslipidaemia is accompanied with increased cardiovascular events in diabetic patients. Today there have been some improvements in the management of dyslipidaemia using lifestyle modification and medications. In this study we evaluate the management of dyslipidaemia in an academic centre.
Material and methods: This is a descriptive study, from January 2003 until December 2007. All type 2 diabetic patients who were more than 30 years old and had at least 2 visits per year were eligible for including.
Results: Overall, 1179 patients (70.2% women) were assessed. Mean LDL-C in 2003 was 124.6 ± 34.6 mg/dL, and decreased to 109.7 ± 28.9 mg/dL in 2007 (p < 0.05). 21.0% of patients in 2003 and 40.5% of them in 2007 had LDL-C < 100 mg/dL. TG did not change during these years. There was an increase in the use of statins from 76.3% to 84.3% (p-value < 0.05) during the 5 years since 2003, but a decrease in the use of fibrates.
Conslusions: Although recently we have made improvements in the control of dyslipidaemia in diabetic patients, we have not reached our goals. Of late, physicians have emphasized the use of statins in diabetic patients, which has resulted in much better levels of LDL-C, but still less than half of the patients are at ideal levels. In conclusion, we should revise our point of view to begin and intensify treatment of dyslipidaemia in diabetic patients, to achieve the goal of treatment and prevent cardiovascular events optimally.

Abstract


Introduction: Dyslipidaemia is accompanied with increased cardiovascular events in diabetic patients. Today there have been some improvements in the management of dyslipidaemia using lifestyle modification and medications. In this study we evaluate the management of dyslipidaemia in an academic centre.
Material and methods: This is a descriptive study, from January 2003 until December 2007. All type 2 diabetic patients who were more than 30 years old and had at least 2 visits per year were eligible for including.
Results: Overall, 1179 patients (70.2% women) were assessed. Mean LDL-C in 2003 was 124.6 ± 34.6 mg/dL, and decreased to 109.7 ± 28.9 mg/dL in 2007 (p < 0.05). 21.0% of patients in 2003 and 40.5% of them in 2007 had LDL-C < 100 mg/dL. TG did not change during these years. There was an increase in the use of statins from 76.3% to 84.3% (p-value < 0.05) during the 5 years since 2003, but a decrease in the use of fibrates.
Conslusions: Although recently we have made improvements in the control of dyslipidaemia in diabetic patients, we have not reached our goals. Of late, physicians have emphasized the use of statins in diabetic patients, which has resulted in much better levels of LDL-C, but still less than half of the patients are at ideal levels. In conclusion, we should revise our point of view to begin and intensify treatment of dyslipidaemia in diabetic patients, to achieve the goal of treatment and prevent cardiovascular events optimally.
Get Citation

Keywords

dyslipidaemia; type 2 diabetes; statins

About this article
Title

Dyslipidaemia and its management in diabetic patients in an academic centre in Iran

Journal

Endokrynologia Polska

Issue

Vol 60, No 5 (2009)

Pages

353-356

Published online

2009-10-30

Bibliographic record

Endokrynologia Polska 2009;60(5):353-356.

Keywords

dyslipidaemia
type 2 diabetes
statins

Authors

Elham Faghihimani
Peyman Adibi
Masoud Amini

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl